Biological markers in the diagnosis of recurrent bladder cancer: An overview

Expert Review of Molecular Diagnostics

Volumn 8, Issue 1, 2008, Pages 63-72

  Mohammed, Aza ^a   Khan, Ziauddin ^a   Zamora, Ignacio ^a   Bhatti, Aftab ^a  

^a UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

Author keywords

Biological marker; Bladder cancer; Diagnosis; Recurrence; Surveillance

Indexed keywords

APROTININ; BIOLOGICAL MARKER; BLOOD GROUP ANTIGEN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR; FAS ANTIGEN; FIBRINOGEN; FIBROBLAST GROWTH FACTOR; HYALURONIC ACID; HYALURONIDASE; MICROSATELLITE DNA; MUCIN 7; NUCLEAR MATRIX PROTEIN 22; PROSTATE STEM CELL ANTIGEN; SURVIVIN; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR ANTIGEN; UROKINASE; UVOMORULIN; TUMOR MARKER;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CELL CYCLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN METABOLISM; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOCYTOCHEMISTRY; MICROSATELLITE INSTABILITY; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY; BLADDER TUMOR; FEMALE; MALE; PATHOLOGY; TUMOR RECURRENCE;

FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 38149007073     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.1.63     Document Type: Review

References (65)

1. Dyrskjot L, Zieger K, Orntoft TF. Recent advances in high-throughput molecular marker identification for superficial and invasive bladder cancers. Front Biosci. 1(12), 2063-2073 (2007).
2. Kausch I, Doehn C, Jocham D. Recent improvements in the detection and treatment of nonmuscle invasive bladder cancer. Expert Rev. Anticancer Ther. 6(9), 1301-1311 (2006).
3. Kitamura H, Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int. J. Clin. Oncol. (11), 28-37 (2006). • Provides a comprehensive review on the management of superficial bladder cancer.
4. Sauter G, Algaba F, Amin M et al. Tumour of the urinary system: non-invasive urothelial neoplasias. In: WHO classification of tumours of the urinary system and male genital organs. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Eds). IARCC Press, Lyon, France (2004).
5. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 22(12), 1435-1448 (1998).
6. O'Donnell MA. Advances in the management of superficial bladder cancer. Semin. Oncol. 34(2), 85-97 (2007).
7. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and resurrence. J. Urol. 130(6), 1083-1086 (1983).
8. Oge O, Erdem E, Atsu N, Ahin A, Ozen H. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumour. Eur. Urol. 37, 271-274 (2000).
9. Oosterlinck, van der Meijden A, Sylvester R et al. Guidelines on TaT1 (Nonm0muscle invasive) bladder cancer. In: European Association of Eurology Guidelines. EUA Guidelines Press (2007).
10. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Euro. Urol. 47, 736-748 (2005). •• Provides a systematic review on the most commonly used biological markers for bladder cancer. It shows the effectiveness of microsatellite instability, MNP22, ImmunoCyt™, CYFRA21-1, Lewis X and FISH as potential diagnostic tools.
11. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21, 1315-1330 (2003).
12. Ross JS. Cohen MB. Detecting recurrent bladder cancer: new methods and biomarkers. Expert Rev. Mol. Diagn. 1(1), 39-52 (2001). • Provides an excellent view on the most commonly used biological markers for bladder cancer with a tabulated comparison in the sensitivity and specificity with urine cytology.
13. Nielsen ME, Gonzalgo ML, Schoenberg MP, Getzenberg RH. Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. World J. Urol. 24(5), 499-508 (2006). •• Provides a comprehensive review on the use of biological markers for the detection of early bladder cancer recurrence.
14. Nielsen ME, Schaeffer EM, Veltri RW, Schoenberg MP, Getzenberg RH. Urinary markers in the detection of bladder cancer: what's new? Curr. Opin. Urol. 16, 350-355 (2006).
15. Grossmand HB, Blute ML, Dinney CP et al. The use of urine-based biomarkers in bladder cancer. Urology 67(3 Suppl. 1), 62-64 (2006).
16. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293, 810-816 (2005).
17. Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295, 299-305 (2006).
18. Shariat SF, Zippe C, Lüdecke G et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J. Urol. 173(5), 1518-1525 (2005).
19. Lokeshwar VB, Schroeder GL, Selzer MG et al. Bladder tumour markers for monitoring recurrence and screening comparison of hyaluronic acid hyaluronidase and BTA-Stat tests. Cancer 95(1), 61-72 (2002).
20. Frazier ML, Su LK, Amos CI, Lynch PM. Current applications of genetic technology in predisposition testing and microsatellite instability assays. J. Clin. Oncol. 18(21 Suppl.), 70S-4S (2000).
21. Mourah S, Cussenot O, Vimont V et al. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int. J. Cancer 79(6), 629-633 (1998).
22. Christensen M, Wolf H, Orntoft TF. Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. Int. J. Cancer 85(5), 614-617 (2000).
23. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol. 168, 1950-1954 (2002).
24. Skacel M, Fahmy M, Brainard JA et al. Mutitarget fluorescence in site hybridization assay detects tranisional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J. Urol. 169(6), 2101-2105 (2003).
25. Kipp BR, Karnes RJ, Brankley SM et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J. Urol. 173, 401-404 (2005).
26. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol. 161(5), 1486-1489 (1999).
27. Messing EM, Teot L, Korman H et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J. Urol. 174(4 Pt 1), 1238-1241 (2005).
28. +/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 108(1), 60-65 (2006).
29. Pfister C, Chautard D, Devonec M et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J. Urol. 169(3), 921-924 (2003).
30. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comprehensive study of point of care tests. J. Urol. 185, 2098-2101 (1997).
31. Sanchini MA, Gunelli R, Nanni O et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 294(16), 2052-2056 (2005).
32. Eissa S, Swellam M, el-Mosallamy H et al. Diagnostic value of urinary molecular markers in bladder cancer. Anticancer Res. 23(5b), 4347-4355 2003).
33. Mellissourgos N, Kastrinakis NG, Davilas I, Foukas P, Farmakis A, Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumour marker. Urology 62(2), 362-367 (2003).
34. Pariente JL, Bordenave L, Jacon F et al. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J. Urol. 163(4), 1116-1119 (2000).
35. Mellissourgos ND, Kastrinakis NG, Skolarikos A et al. Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology 66 (3), 536-541 (2005).
36. Christoph F, Weikert S, Wolf I et al. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett. 245(1-2), 121-126 (2007).
37. Nagata S, Golstein P. The Fas death factor. Science 267, 1449-1456 (1995).
38. Svatek RS, Herman MP, Lotan Y et al. Soluble Fas - a promising novel urnary marker for the detection of recurrenet superficial bladder cancer. Cancer 106(8), 1701-1707 (2006).
39. Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother. Radiopharm. 17(5), 563-567 (2002).
40. Vivani C, Magi S, Mazzucchelli R et al. Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia. Anal. Quant. Cytol. Histol. 26(1), 15-21 (2004).
41. Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 61(5), 1053-1058 (2003).
42. Myers-Irvin JM, Van Le TS, Getzenberg RH. Mechanistic analysis of the role of BLCA-4 in bladder cancer pathophysiology. Cancer Res. 65(16), 7145-7150 (2005).
43. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based markers of bladder cancer. Urology 66(6), 1256-1260 (2005).
44. Chopin DK, Caruelle JP, Colombel M et al. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J. Urol. 150(4), 1126-1130 (1993).
45. Van Oers JM, Lurkin I, van Exsel AJ et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations I bladder cancer and voided urine. Clin. Cancer Res. 11(21), 7743-7748 (2005).
46. Politi EN, Lazaris AC, Lambropoulous S, Alexopoulou D, Kyriakidou V, Koutselini H. Epidermal growth factor receptor and proliferating cell nuclear antigen expression in urine ThinPrep specimens. Cytopathology 16(6), 303-308 (2005).
47. Pham HT, Block NL, Lokeshwar VB. Tumour-derived hyaluronidase: a diagnostic urine marker for high grade bladder cancer. Cancer Res. 57(4), 778-783 (1997).
48. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altier DC. Urine detection of surviving and diagnosis of bladder cancer. JAMA 285(3), 324-328 (2001).
49. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Saqalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression and mortality. Cancer 109(6), 1106-1113 (2007).
50. Protheroe AS, Banks RE, Mzimba M et al. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer. Br. J. Cancer 80, 273-278 (1999).
51. Shariat SF, Matsumoto K, Casella R, Jian W, Lerner SP. Urinary levels of soluble E-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur. Urol. 48(1), 69-76 (2005).
52. Chen WT. Membrane proteases: roles in tissue remodelling and tumour invasion. Curr. Opin. Cell Biol. 4(5), 802-809 (1992).
53. Nakopoulou L, Gakiopoulou H, Zervas A et al. MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl. Immunohistochem. Mol. Morphol. 9, 130-137 (2001).
54. Guan KP, Ye HY, Yan Z, Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 61, 719-723 (2003).
55. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol. 49, 187-198 (2004).
56. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br. J. Cancer 77, 650-655 (1998).
57. Stenman UH. Tumour-associated trypsin inhibitor. Clin. Chem. 48(8), 1206-1209 (2002).
58. Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol. 6, 19 (2006).
59. Kelloniemi E, Rintala E, Finne P, Stenman UH. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 62(2), 249-253 (2003).
60. Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumour-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur. Urol. 48, 424-431 (2005).
61. Friedrich MG, Hellstern A, Hautmann SH, Noldus I, Huland H. Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12. Urologe A 42(4), 523-530 (2003).
62. Perex-Vilar J, Hill RL. Mucin family of glycoprotiens. In: Encyclopedia of Biological Chemistry. Lennarz WJ, Lane MD (Eds). Academic Press Elsvier, Oxford, UK. 2, 758-764 (2004).
63. Okegawa T, Kinjo M, Horie S, Horie S, Nutahara K, Higashihara E. Detection of Mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumour. Urology 62, 182-186 (2003).
64. Cheng L, Reiter RE, Jin Y et al. Immunocytochemical analysis of prostate stem cell antigen as an adjunct marker for the detection of urothelial transitional cell carcinoma in voided urine specimens. J. Urol. 169, 2094-2100 (2003).
65. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol. Cell. Proteomics 5(10), 1760-1771 (2006).